Canopy Growth posts C$0.10 loss on C$81.37m revenue

By Grace Kim

C$81.37 million in quarterly revenue, a C$0.10 loss per share, a 73.95% negative net margin and a 29.85% negative return on equity marked Canopy Growth Corporation’s Friday earnings results.

The numbers show sales but negative profitability. The forward test is whether the next quarter produces more revenue with a smaller loss.

What did Canopy report for the quarter?

Canopy Growth Corporation, listed on the Toronto Stock Exchange under WEED, issued its earnings results Friday. FiscalAI’s quarterly figures showed:

• Revenue: C$81.37 million.
• Earnings per share (profit or loss allocated to each share): C($0.10), meaning a loss of 10 cents per share.
• Net margin (net loss as a share of revenue): negative 73.95%, or 73.95 cents of net loss for each C$1 of reported revenue.
• Return on equity (net profit or loss relative to shareholders’ equity): negative 29.85%.

Revenue reached C$81.37 million, but the margin and ROE readings show losses relative to revenue and shareholder capital.

Takeaway: Canopy made C$81.37 million in sales but lost 10 cents per share, with both margin and shareholder-return measures negative.

What do the balance-sheet ratios say?

Three reported ratios put the balance sheet in context:

• Debt-to-equity, comparing reported borrowings with shareholders’ equity: 40.27.
• Quick ratio, counting assets expected to convert quickly against current liabilities: 2.32.
• Current ratio, comparing all current assets with current liabilities: 3.04.

The quick and current ratios both exceed 1.00, meaning the asset coverage described by each measure exceeds current liabilities. By contrast, the 40.27 debt-to-equity ratio equates to 40.27 units of reported debt for each unit of equity used in the calculation.

Future earnings reviews will focus on whether the quick and current ratios remain above 1.00 while debt-to-equity falls as losses narrow. The reported ratios do not show debt maturities or interest costs.

Takeaway: The figures show stronger short-term asset coverage than equity backing for debt.

Where did the shares stand?

Canopy’s stock opened at C$0.92 on Friday, C$0.08 above its C$0.84 52-week low and C$2.36 below its C$3.28 high.

The opening price sat C$0.26 below the C$1.18 50-day moving average and C$0.46 below the C$1.38 200-day moving average. These two measures summarize average prices over 50 and 200 trading days. The company’s market capitalization—the equity value of its listed shares—stood at C$389.19 million.

Three valuation and trading measures add context:

• Price-to-earnings ratio, which compares share price with earnings: -1.37.
• Price-to-earnings-growth ratio, a growth-adjusted version of that measure: -0.01.
• Beta, a measure of sensitivity to broader market moves: 2.07.

Negative earnings produced negative P/E and PEG values rather than positive multiples. A beta of 2.07 points to greater market sensitivity than a beta of 1.00, which marks market-level movement.

Takeaway: The C$0.92 opening price was below both moving averages and near the bottom of the C$0.84-C$3.28 annual range.

Who sold shares?

Director David Angelo Lazzarato sold 22,380 Canopy shares in a transaction dated Monday, September 28. The sale carried an average price of C$1.29 and a total value of C$28,870.20.

Afterward, Lazzarato directly owned 108,237 shares worth C$139,625.73. The transaction reduced the director’s direct ownership by 17.13%.

Across the last 90 days, insiders sold 43,492 shares worth a reported $56,105, and corporate insiders owned 0.21% of the stock. The disclosure gave no motive for the sale, but the change in ownership was clear.

Future ownership filings will show whether insider sales continue, stop or reverse, and whether the 0.21% insider stake changes.

Takeaway: The disclosed transaction cut one director’s holdings by 17.13% while corporate insiders retained only 0.21% of the stock.

What does Canopy sell?

Canopy Growth Corporation, together with its subsidiaries, grows, possesses and sells medical cannabis—cannabis intended for therapeutic use—in Canada. Its products include dried flowers, oils and concentrates, softgel capsules and hemp.

The company sells those products under Tweed, Black Label, Spectrum Cannabis, DNA Genetics, Leafs By Snoop, CraftGrow and Foria. Tweed Main Street operates as a single online platform that enables registered patients to purchase medicinal cannabis from various producers across various brands.

The platform gives registered patients access to products from multiple producers and brands rather than limiting purchases to Canopy’s own portfolio. The earnings summary did not disclose platform revenue, user counts or transaction volumes.

Takeaway: Canopy sells cannabis products and runs one website where registered patients can buy from several producers.

What matters next?

The next earnings release offers a direct benchmark: C$81.37 million of revenue, a C$0.10 loss per share and a 73.95% negative net margin. A smaller loss and movement toward positive net margin and ROE would mark the clearest operating improvement.

Future filings will show whether the debt-to-equity, quick and current ratios improve while liquidity remains sufficient. Ownership updates will show whether insider selling continues.

Bottom line: Canopy reported C$81.37 million of revenue but remained loss-making; the next report will show whether losses narrow without weakening liquidity.